首页 > 市场调查报告书 > 医疗设备

药物递输设备

市场调查报告书

商品编码

1534243

全球口腔给药系统市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势与预测

Global Buccal Drug Delivery System Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年07月01日 | 出版商:

Value Market Research | 英文 171 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

全球口腔给药系统市场需求预计将从 2023 年的 47 亿美元达到 2032 年近 84.1 亿美元的市场规模，2024-2032 年研究期间复合年增长率为 6.68%。

口腔给药系统是指透过脸颊或口底的黏膜内层给药。此途径可让药物绕过胃肠道和肝臟代谢，有可能提高生物利用度和治疗效果。口腔给药系统有多种形式，包括贴片、片剂和薄膜，旨在黏附在口腔黏膜上并释放药物以直接吸收到血液中。

市场动态

在多种因素的推动下，口腔给药系统市场可望显着成长。首先，患者对非侵入性给药方法的偏好，加上给药的便利性和患者依从性的提高，促进了口腔给药系统的采用。製药公司越来越投入研发资金来开发可增强药物吸收和作用持续时间的新型配方。此外，透过口腔途径输送小分子和生物製剂的潜力扩大了各个治疗领域的应用范围，包括疼痛管理、荷尔蒙治疗和神经系统疾病。此外，黏膜黏附聚合物和渗透增强剂等配方技术的进步克服了药物吸收的障碍并改善了治疗效果，有助于市场的扩张。监管机构越来越多地接受口腔给药系统作为传统途径的有效且安全的替代品，这进一步促进了市场的成长。

此外，全球人口老化和慢性病的盛行率上升推动了对创新药物输送解决方案的需求，这些解决方案可提高疗效并减少副作用。此外，製药公司和研究机构之间的合作促进了针对特定患者需求的客製化口腔配方的开发，透过产品差异化和扩大市场渗透率促进市场成长。然而，严格的监管要求和在患者群体中实现一致的药物吸收率的挑战可能会阻碍口腔给药系统市场的成长。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对口腔给药系统全球市场的各个细分市场进行了包容性评估。口腔给药系统产业的成长和趋势为本研究提供了整体方法。

市场区隔

口腔给药系统市场报告的这一部分提供了国家和区域层面细分市场的详细资料，从而帮助策略家确定相应产品或服务的目标人群以及即将到来的机会。

按类型

舌下膜和薄片
含片/含片
口腔喷雾剂

按申请

疼痛管理
戒烟
心绞痛
其他的

按最终用途

医院
门诊中心
其他（诊所、家庭健康/非处方药）

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲口腔给药系统市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。口腔给药系统市场的主要参与者包括 GSK Plc、Teva Pharmaceutical Industries Ltd.、辉瑞 Inc.、Generex Biotechnology Corporation (Lumitos AG)、ARx LLC.、Endo Inc.、Catalent Inc.、Cynapsus Therapeutics Inc.、Collegium Pharmaceutical ，独立PLC。本节包含竞争格局的整体视图，包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

区域展望
介绍
北美销售分析
- 概览、历史与预测资料销售分析
- 北美按细分市场销售分析
- 北美按国家销售分析
- 美国销售分析
- 加拿大销售分析
- 墨西哥销售分析
欧洲销售分析
- 概览、历史与预测资料销售分析
- 欧洲按细分市场销售分析
- 欧洲按国家销售分析
- 英国销售分析
- 法国销售分析
- 德国销售分析
- 义大利销售分析
- 俄罗斯销售分析
- 欧洲其他地区销售分析
亚太地区销售分析
- 概览、历史与预测资料销售分析
- 亚太地区按细分市场销售分析
- 亚太地区按国家销售分析
- 中国销售分析
- 印度销售分析
- 日本销售分析
- 韩国销售分析
- 澳洲销售分析
- 东南亚销售分析
- 亚太地区其他地区销售分析
拉丁美洲销售分析
- 概览、历史与预测资料销售分析
- 拉丁美洲按细分市场销售分析
- 拉丁美洲按国家销售分析
- 巴西销售分析
- 阿根廷销售分析
- 秘鲁销售分析
- 智利销售分析
- 拉丁美洲其他地区销售分析
中东和非洲销售分析
- 概览、历史与预测资料销售分析
- 中东和非洲按细分市场销售分析
- 中东和非洲按国家销售分析
- 沙乌地阿拉伯销售分析
- 阿联酋销售分析
- 以色列销售分析
- 南非销售分析
- 中东其他地区和非洲销售分析

第 9 章：口腔给药系统公司的竞争格局

口腔给药系统市场竞争
伙伴关係/协作/协议
併购
新产品发布
其他发展

第 10 章：公司简介

顶级公司市占率分析
市场集中度
GSK Plc

公司概况
公司收入
产品
最新动态

Teva Pharmaceutical Industries Ltd.

公司概况
公司收入
产品
最新动态

Pfizer Inc.

公司概况
公司收入
产品
最新动态

Generex Biotechnology Corporation (Lumitos AG)

公司概况
公司收入
产品
最新动态

ARx LLC.

公司概况
公司收入
产品
最新动态

Endo Inc.

公司概况
公司收入
产品
最新动态

Catalent Inc

公司概况
公司收入
产品
最新动态

Cynapsus Therapeutics Inc.

公司概况
公司收入
产品
最新动态

Collegium Pharmaceutical

公司概况
公司收入
产品
最新动态

Indivior PLC

公司概况
公司收入
产品
最新动态

註 - 在公司概况中，财务详细资讯和最新发展视情况而定，或对私人公司而言可能不包括在内

简介目录图表

Product Code: VMR112115326

The global demand for Buccal Drug Delivery System Market is presumed to reach the market size of nearly USD 8.41 Billion by 2032 from USD 4.7 Billion in 2023 with a CAGR of 6.68% under the study period 2024-2032.

The buccal drug delivery system refers to administering medications through the mucosal lining of the cheek or the floor of the mouth. This route allows drugs to bypass the gastrointestinal tract and liver metabolism, potentially improving bioavailability and therapeutic efficacy. Buccal delivery systems come in various forms, including patches, tablets, and films, designed to adhere to the buccal mucosa and release medications for absorption directly into the bloodstream.

MARKET DYNAMICS

The buccal drug delivery system market is poised for significant growth driven by several factors. Firstly, patient preference for non-invasive drug delivery methods, coupled with the ease of administration and improved patient compliance, boosts the adoption of buccal delivery systems. Pharmaceutical companies are increasingly spending R&D to develop novel formulations that enhance drug absorption and duration of action. Moreover, the potential for delivering small molecules and biologics through the buccal route expands the application scope across various therapeutic areas, including pain management, hormonal therapies, and neurological disorders. Furthermore, advancements in formulation technologies such as mucoadhesive polymers and permeation enhancers contribute to the market's expansion by overcoming barriers to drug absorption and improving therapeutic outcomes. Regulatory agencies' growing acceptance of buccal drug delivery systems as effective and safe alternatives to traditional routes further catalyzes market growth.

Moreover, the aging population and the rising prevalence of chronic diseases worldwide drive the demand for innovative drug delivery solutions that offer enhanced efficacy and reduced side effects. Additionally, partnerships between pharmaceutical companies and research institutions facilitate the development of customized buccal formulations tailored to specific patient needs, fostering market growth through product differentiation and expanded market penetration. However, stringent regulatory requirements and challenges in achieving consistent drug absorption rates across patient populations can hamper buccal drug delivery system market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Buccal Drug Delivery System. The growth and trends of Buccal Drug Delivery System industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Buccal Drug Delivery System market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

Sublingual Films and Wafers
Buccal Tablets/Lozenges
Oral Sprays

By Application

Pain Management
Smoking Cessation
Angina Pectoris
Others

By End-use

Hospitals
Ambulatory Centers
Others (Clinics, Home Health/OTC)

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Buccal Drug Delivery System market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Buccal Drug Delivery System market include GSK Plc, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Generex Biotechnology Corporation (Lumitos AG), ARx LLC., Endo Inc., Catalent Inc, Cynapsus Therapeutics Inc., Collegium Pharmaceutical, Indivior PLC. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. BUCCAL DRUG DELIVERY SYSTEM - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Type
- 3.7.2 Market Attractiveness Analysis By Application
- 3.7.3 Market Attractiveness Analysis By End-use
- 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL BUCCAL DRUG DELIVERY SYSTEM MARKET ANALYSIS BY TYPE

5.1. Overview By Type
5.2. Historical and Forecast Data Analysis By Type
5.3. Sublingual Films and Wafers Historic and Forecast Sales By Regions
5.4. Buccal Tablets/Lozenges Historic and Forecast Sales By Regions
5.5. Oral Sprays Historic and Forecast Sales By Regions

6. GLOBAL BUCCAL DRUG DELIVERY SYSTEM MARKET ANALYSIS BY APPLICATION

6.1. Overview By Application
6.2. Historical and Forecast Data Analysis By Application
6.3. Pain Management Historic and Forecast Sales By Regions
6.4. Smoking Cessation Historic and Forecast Sales By Regions
6.5. Angina Pectoris Historic and Forecast Sales By Regions
6.6. Others Historic and Forecast Sales By Regions

7. GLOBAL BUCCAL DRUG DELIVERY SYSTEM MARKET ANALYSIS BY END-USE

7.1. Overview By End-use
7.2. Historical and Forecast Data Analysis By End-use
7.3. Hospitals Historic and Forecast Sales By Regions
7.4. Ambulatory Centers Historic and Forecast Sales By Regions
7.5. Others (Clinics, Home Health/OTC) Historic and Forecast Sales By Regions

8. GLOBAL BUCCAL DRUG DELIVERY SYSTEM MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE BUCCAL DRUG DELIVERY SYSTEM COMPANIES

9.1. Buccal Drug Delivery System Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10. COMPANY PROFILES OF BUCCAL DRUG DELIVERY SYSTEM INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. GSK Plc
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
10.4. Teva Pharmaceutical Industries Ltd.
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
10.5. Pfizer Inc.
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
10.6. Generex Biotechnology Corporation (Lumitos AG)
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
10.7. ARx LLC.
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
10.8. Endo Inc.
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
10.9. Catalent Inc
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
10.10. Cynapsus Therapeutics Inc.
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
10.11. Collegium Pharmaceutical
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments
10.12. Indivior PLC
- 10.12.1 Company Overview
- 10.12.2 Company Revenue
- 10.12.3 Products
- 10.12.4 Recent Developments